Subscribe
istock-175506089_kerrick
Kerrick / iStockphoto.com
18 June 2018Americas

Indivior obtains court order to block generic Suboxone

Addiction treatment drug producer  Indivior has obtained a temporary restraining order against Indian generic maker Dr Reddy’s, blocking the company from launching a generic version of Suboxone (buprenorphine and naloxone) Film.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Indivior loses battle over Suboxone generic
22 November 2018   The US Court of Appeals for the Federal Circuit vacated a preliminary injunction against India-based Dr Reddy’s earlier this week, in a blow for addiction treatment drug producer Indivior.
Americas
Indivior settles addiction drug dispute with Par
16 May 2018   Addiction drug producer Indivior has settled its patent infringement dispute with generics manufacturer Par Pharmaceutical.
Americas
Indivior pledges to appeal generic Suboxone decision
26 March 2018   UK-based Indivior has pledged to appeal a US court decision that found a drug developed by generics maker Alvogen doesn’t infringe three of Indivior’s patents.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Indivior loses battle over Suboxone generic
22 November 2018   The US Court of Appeals for the Federal Circuit vacated a preliminary injunction against India-based Dr Reddy’s earlier this week, in a blow for addiction treatment drug producer Indivior.
Americas
Indivior settles addiction drug dispute with Par
16 May 2018   Addiction drug producer Indivior has settled its patent infringement dispute with generics manufacturer Par Pharmaceutical.
Americas
Indivior pledges to appeal generic Suboxone decision
26 March 2018   UK-based Indivior has pledged to appeal a US court decision that found a drug developed by generics maker Alvogen doesn’t infringe three of Indivior’s patents.

More on this story

Americas
Indivior loses battle over Suboxone generic
22 November 2018   The US Court of Appeals for the Federal Circuit vacated a preliminary injunction against India-based Dr Reddy’s earlier this week, in a blow for addiction treatment drug producer Indivior.
Americas
Indivior settles addiction drug dispute with Par
16 May 2018   Addiction drug producer Indivior has settled its patent infringement dispute with generics manufacturer Par Pharmaceutical.
Americas
Indivior pledges to appeal generic Suboxone decision
26 March 2018   UK-based Indivior has pledged to appeal a US court decision that found a drug developed by generics maker Alvogen doesn’t infringe three of Indivior’s patents.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB